NanoBio makes appointment
This article was originally published in Scrip
NanoBio (US) has appointed Dr Daniel Dubin to its board of directors. He is vice-chairman and a director at Leerink Swann, a healthcare and biotechnology investment banking firm. NanoBio is a private biopharmaceutical company developing and commercialising anti-infective products and mucosal vaccines derived from its NanoStat technology platform.
You may also be interested in...
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.